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With the world’s largest national treatment programme and over 340 000 incident cases 
annually, the response to HIV in South Africa is hotly contested and there is sometimes a 
dissonance between activism, science and policy. Too often, policy, whilst well intentioned, is 
informed only by epidemiological data. The state of the healthcare system and sociocultural 
factors drive and shape the epidemic and its response. By analysis of the financial, 
infrastructural, human resources for health, and governance landscape in South Africa, 
we assess the feasibility and associated costs of implementing a universal test and treat 
programme. We situate a universal test and treat strategy within the governance, fiscal, 
human resources for health, and infrastructural landscape in South Africa. We argue that the 
response to the epidemic must be forward thinking, progressive and make the most of the 
benefits from treatment as prevention. However, the logistics of implementing a universal 
test and treat strategy mean that this option is problematic in the short term. We recommend 
a health systems strengthening HIV treatment and prevention approach that includes scaling 
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South Africa currently has the world’s highest national incidence of HIV and AIDS, with 6.4 
million people infected and over 340 000 incident cases annually.1 The history of the epidemic and 
the political, economic and policy response has been well documented by academics.2,3,4 In brief, 
the government refused from 1999 to 2004 to provide antiretroviral therapy via public facilities. 
The then Head of State, Thabo Mbeki, aided and abetted by Minister of Health Manto Tshabalala-
Msimang, a few members of his cabinet and some of the provincial governments, questioned the 
causal link between the HI virus and AIDS, the effects of antiretroviral therapy (ART), and the 
motives of pharmaceutical companies.5 Despite this opposition, drugs were made available by 
progressive provincial governments, health workers and activist organisations. Since those bleak 
days of AIDS denialism, and increasingly from 2005,5 South Africa has expanded its HIV services 
and today has the world’s largest ART programme, reaching about 2.1 million people.1
Like most countries in sub-Saharan Africa, South Africa tries to base its health policy on World 
Health Organization (WHO) recommendations. Their guidelines are based on the best available 
scientific evidence, but do not always speak to economic and social realities, especially regarding 
HIV and AIDS. The first WHO HIV treatment guidelines were released in 2002, and updated in 
2006, 2010 and 2013. The latest WHO clinical recommendations promote treatment initiation for 
adults and adolescents > 10 years old whose CD4 count falls below 500 cells/mm3 and immediate 
treatment for persons with active TB disease; hepatitis B virus (HBV) co-infection with severe 
chronic liver disease; pregnant and breastfeeding women with HIV; and those who are HIV-
positive in a serodiscordant partnership.6
The South African National Department of Health adopted the 2010 recommendations to start 
adults on treatment at a CD4 cell count ≤ 350 cells/mm3, and in 2015 partially adopted the 
new guidelines.7 The only WHO recommendation not adopted in the new South African ART 
guidelines is the recommendation to initiate serodiscordant couples regardless of CD4 count; the 
discussion of whether or not to include this is ongoing. However, the government is hesitant to 
start all HIV-infected individuals on treatment irrespective of CD4 level.
Historically, WHO recommendations drive policy. In the light of the delayed and discrepant 
policy change in South Africa, it is worth examining the WHO recommendations and process 
with careful consideration of context. Whilst scientific evidence provides the foundation for the 
WHO’s guidance on expanded treatment eligibility, scientific literature tends to be produced in a 
vacuum. Increasing the CD4 threshold has implications that reverberate across sectors: it affects 
budgets, infrastructure and human resources.
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In the present article, we examine how policy has changed 
and existing constraints on the South African government. 
The policy debate has been articulated in the pages of this 
journal, but it is noteworthy that this is the only place where 
we have seen these arguments7,8 as they are generally seen as 
politically incorrect and going against international norms.
We argue that policymakers must consider the possibility 
that a ’one-size-fits-all’ approach to treatment may not be 
the most beneficial for patients’ health and adherence to 
treatment, or the most cost-effective for the national budget.7 
Decisions to change the CD4 threshold in South Africa are 
not taken lightly, but we are not convinced that there has 
been sufficient consideration of the implications regarding 
capacity, adherence and the health of the population. We 
argue that the treatment agenda has been set outside the 
country and to unrealistic levels reflecting a dissonance 
between activism, science and policy.9
The success in translating evidence into practice depends 
on local context, resources, priorities and data. It is our 
view that the South African government’s position is that it, 
reluctantly, has to change policy if not practice. This works 
for a relatively well-off country with a powerful political 
leadership, reasonable public health system, low (and falling) 
dependence on donors, and a reasonable public platform for 
debate. In many other settings, governments and ministries 
of health may be adversely affected by the decrees from 
Geneva or global capitals.
The present article identifies two major challenges faced in 
South Africa. First, modelling studies are being given too 
much emphasis and should not be used, in isolation, to 
dictate policy. Second, the issue of when to provide ART is 
being conflated with treatment-based prevention.
It is important, however, to understand the two pressures 
for treatment. First, it is seen by some as a ‘right’ that HIV-
positive people should get the best available treatment, 
without considering the broader health context and the 
need to make choices. Second is the pressure of treatment 
as prevention. The seminal HPTN 052 study showed the 
effectiveness of ART in reducing HIV transmission in 
discordant heterosexual couples.10 This study was a key driver 
for the WHO to revise its guidelines for ART initiation.11 ART 
is recommended for HIV–positive, pregnant, breastfeeding 
women; all children under the age of five; people with TB 
or hepatitis B; and HIV–positive people with HIV-negative 
partners.6
For clarity, we include working definitions of Universal 
Access and Universal Test and Treat ART rollout strategies 
as well as treatment as prevention (TasP) (see panel). 
Papers12,13,14,15 that model the cost-effectiveness of universal 
test and treat in South Africa, using various inputs and 
assumptions, yield different results. We include an 
overview of the findings and conclusions of these studies 
to show the different predicted outcomes and costs of 
universal test and treat.
Models are a mixed blessing – they can generate useful cost-
effectiveness data if they are based on realistic assumptions 
and up to date biomedical data. However, achieving this 
often proves to be difficult, especially for long-term analyses, 
because even small inaccuracies or unforeseen costs may 
lead to very different results. Meyer-Rath and Over15 warn 
about the shortcomings of ART scale-up models that do not 
account for the flexibility of costs over time. Their model 
showed that small-scale inefficiencies could lead to far higher 
costs in the long run.
Although prevention necessarily results from any treatment 
programme,16 it is important when developing policy not 
to conflate TasP with universal test and treat. We critique 
universal test and treat in the context of governance, human 
resources for health, and infrastructural and fiscal constraints 
in South Africa. The response to the epidemic must be forward 
thinking, progressive and to make the most of the benefits 
from TasP. The logistics of implementing a universal test 
and treat strategy mean that this option is problematic in the 
short term. We recommend a health systems strengthening 
HIV treatment and prevention approach, which includes 
scaling up treatment (for treatment and prevention) along 
with a range of other prevention strategies.
Governance
South Africa’s Constitution established three spheres of 
government–national, provincial, and local. Health policy 
is developed nationally and adapted to fit provincial needs. 
Healthcare funding, including that for HIV and AIDS, is 
allocated to provincial departments of health. This system 
has created and exacerbated health inequities between 
provinces. The political, socioeconomic and historical context 
in the nine provinces varies significantly, which affects 
service delivery (see Table 1).17 We illustrate this point with 
data from the best and worst provinces: the well-resourced 
and well-governed Western Cape, and Limpopo which has 
a largely rural population, fewer human resources per capita 
and inefficient government.
The health profile in South Africa’s nine provinces varies 
between these two extremes. HIV prevalence ranges from 
4.75% in the Western Cape to 24.7% in KwaZulu-Natal – nearly 
double that in Limpopo. The number of annual new HIV 
infections varies by a factor of 30.18 In this context, one-size-
fits-all interventions cannot work; the gaps in health service 
facilities, especially staffing levels, are too great. A blanket 
universal test and treat strategy would be difficult to apply.
Human resources for health 
capacity
Human resources are a significant limitation on the ability 
to effectively deliver health and HIV services. Progress has 
been made; the number of public sector doctors increased 
from 7645 in 2003 to 13 614 in 2013, and the number of 
professional nurses registered with the South African 
Nursing Council from 96 715 to 129 015.19 The number of 
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doctors and professional nurses per 100 000 people exceeds 
the WHO minimum.
The problem is the uneven distribution of human resources 
for health (HRH) across provinces; between urban and rural 
areas; and between the public and private sectors.19 Only 
12% of the country’s doctors and 19% of its nurses work 
in rural facilities, serving 43.6% of the population.20 These 
additional strains on an already overstretched health labour 
force compromise the ability of the health system to provide 
equal access and increased coverage of treatment and care for 
people with HIV.
Health facilities face other human resource problems. The 
real unit costs of labour have almost doubled over the last 
15 years.19 Put simply, this means that compensation has 
gone up more than productivity, hence more money has to 
be spent to achieve the same result. Attrition owing to AIDS 
and emigration has worsened the ratio of professional and 
enrolled nurses and doctors to population size in the public 
sector. There is an historical trend of a substantial proportion 
of doctors who qualified in South Africa emigrating to work 
abroad, and many leave the public sector to work in private 
practice.20
Responses include expanding and auditing the quality 
and relevance of training to meet the demand for health 
services, task shifting and developing strategies for ensuring 
an equitably distributed, long-term supply of HRH. 
Government’s training targets may enable South Africa to 
reach universal ART, if the skewed distribution of HRH 
is addressed in conjunction with innovative, task shifting 
measures. Building human resource capacity to meet the 
needs of a universal test and treat programme will be a 
significant challenge in South Africa and will need to be an 
increasing priority as the treatment programme expands.
Infrastructural capacity
South Africa’s healthcare infrastructure has improved 
since 1994, but regional and sectoral discrepancies persist 
(Table 1). Fifteen per cent of poor rural households live 
TABLE 1: Provincial inequality.
Indicator Limpopo Western Cape
Contribution to gross domestic product (2010) 7.2% 14.1%
Percentage of total population 10.4% 11.2%
Percentage of rural population 90% 10%
HIV prevalence (ages 15–49) 12.92% 4.75%
Number of people living with HIV 409 161 273 114
Number of private hospitals 8 34
Number of public hospitals 42 55
Number of public sector doctors per 100 000 population 20.7 34.8
Health professional vacancy rate 58.5% 29.0%
Data compiled from the public domain.
BOX 1: Definitions and models.
Definitions
Universal access: Treating 80% of HIV-infected individuals with CD4 count < 350 cells/μL, offering ART for discordant couples regardless of CD4 count32
Universal test and treat: Treating all HIV-infected individuals irrespective of CD4 count13
Treatment as prevention: HIV prevention methods that use ART in HIV-positive persons to decrease the chance of HIV transmission independent of CD4 count11
Models estimating the cost and cost-effectiveness of universal test and treat in South Africa
Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa: Estimated cost and cost-effectiveness 2011–2050. PLoS ONE 2012; 
7:e30216.
Findings:
•  Model predicts universal access (at CD4 < 350 cells/μL) would reduce new HIV infections by an estimated 265 000 over 5 years and 1.4 million over 40 years.
•  Universal access could reduce estimated deaths by 200 000 and save US$504 million over 5 years. Over 40 years, it could reduce deaths by 2.9 million, DALYs by 15.7 million, 
and costs by $3.9 billion.
•  Achieving universal test and treat would result in a further decline of 3.3 million infections, 3.5 million deaths, 25.7 million DALYs, and would cost $10 million less over 40 years, 
compared with achieving universal access.
•  Conclusion: A universal test and treat programme is an optimal implementation of TasP.
Wagner BG, Blower S. Universal access to HIV treatment versus universal ‘test and treat’: Transmission, drug resistance and treatment costs. PLoS ONE 2012;7:e41212.
Findings:
•  Model finds that a universal test and treat strategy could eliminate HIV after 40 years and would cost $12 billion more than achieving universal access.
•  Achieving universal access would prevent 4 million infections after 20 years and 11 million after 40 years.
•  Conclusion: A universal access programme is a better implementation of TasP than universal test and treat.
Meyer-Rath G, Over M. HIV treatment as prevention: Modelling the cost of antiretroviral treatment—state of the art and future directions. PLoS Med. 2012;9: e1001247. 
http://dx.doi.org/10.1371/journal.pmed.1001247
Findings:
•  Many existing models of TasP and ART scale-up do not use realistic assumptions about costs and cost structures, and therefore cannot accurately predict costs – especially in 
the long term.
•  Conclusion: A universal test and treat programme in South Africa will cost 42% more than the cost predicted by the WHO model.
Bärnighausen T, Bloom DE, Humai S. Economics of antiretroviral treatment vs. circumcision for HIV prevention. PNAS. 2012;109:21271–21276.
Findings:
•  Model finds universal access combined with high medical male circumcision coverage provides approximately the same HIV incidence reduction as universal test and treat, for 
$5 billion less over 2009 – 2020.
•  Conclusion: Universal access and high MMC coverage is a better combination prevention strategy than universal test and treat, and better use of the benefits of TasP.
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more than one hour away from the closest clinic, and 20% 
live more than one hour away from the closest hospital.21 
The fragility of the health system was clearly illustrated 
in December 2012 when Médecins Sans Frontières had to 
step in to supply the Mthatha medical depot with ARVs 
for 50 000 HIV-infected patients. An estimated 5494 adults 
taking ARVs went at least one day without treatment owing 
to severe drug supply and delivery disruptions.22,23 This 
service delivery crisis was a symptom of long-standing 
and systemic infrastructural, human resource capacity and 
financial mismanagement issues, which continue today.24
A universal test and treat programme would place strain on 
a fragile system, possibly particularly compromising rural 
healthcare where there may be fewer staff members, and also 
a dependence on urban-based supply chains. South Africa’s 
public health infrastructure must be strengthened to support 
the demands of universal ART and the proposed National 
Health Insurance (NHI) plan.
Financial capacity
A good understanding of South Africa’s healthcare spending 
shows additional constraints. Overall expenditure on public 
health grew from R16.4 billion in 2008/2009 to over R30 
billion in 2013/2014.25 A key component of the expanded 
health budget is the NHI plan, to be phased-in over 14 years. 
This plan aims to restructure and strengthen the public 
health system and improve quality of care. The NHI will 
require significant financial expenditure, imposing a further 
fiscal burden on taxpayers. NHI-related public spending 
increased from R119.3 million in 2008/2009 to R491.8 million 
in 2013/2014, and is expected to increase to R650.1 million by 
2016/2017.25
This expense must be seen against a backdrop of rising HIV 
spending. Public spending on HIV and AIDS increased from 
R3.36 billion in 2008/2009 to R10.97 billion in 2013/2014.25 
Clinical care and treatment support from the President’s 
Emergency Plan for AIDS Relief (PEPFAR), South Africa’s 
largest bilateral donor, will come to an end in 2017, and the 
focus of this funding is already shifting from treatment to 
support and technical assistance. The government committed 
to increase its financing of the National Strategic Plan for HIV, 
STIs and TB (NSP) from R9.57 billion in 2012 (71% of NSP) 
to R15.2 billion in 2017 (88% of NSP).26 Despite this outlay, 
the government is forecasting a widening funding gap; in 
2013/2014 it was R2.67 billion. By 2015/2016 the projections 
are: resource needs of R29.86 billion, government funding 
of R19.8 billion, and development partners providing 
R5.02 billion – leaving a gap of over R5 billion.27
A universal test and treat strategy does not currently fit into 
South Africa’s available financial resources and spending 
priorities. Although NHI expenditure will strengthen HIV 
services, it crowds out the feasibility of investment in a 
universal test and treat programme unless significant new 
money is allocated; this could come from re-allocation of 
national budgets but would require political will.
Treating the region?
There is evidence of an increasing burden on existing health 
resources because of ’medical tourists’ in South Africa, 
especially from neighbouring countries. In 2012 there were 
6 689 105 African or Middle Eastern visitors to South Africa, 
of whom 260 875 or 3.9% were defined as medical tourists. 
Not all are seeking public health; middle-class visitors 
may be coming for elective procedures or be covered by 
insurance; and some regional governments refer (and pay 
for) patients to attend specialised medical facilities and this 
is covered under the 1999 Southern African Development 
Community (SADC) Health Protocol.28
There is evidence to show that, as ART coverage improves 
across the border, so the number of people trying to access 
treatment in South Africa declines. In the case of Botswana, 
medical tourists grew from 40 000 to just over 50 000 between 
2003 and 2008. Thereafter, the numbers fell to less than 
20 000 in 2012. For Mozambique, the number of medical 
tourists grew rapidly from 8000 in 2003 to about 180 000 in 
2010. With the expansion of ART coverage in Mozambique, 
the numbers fell and in 2012 were just less than 100 000.28 The 
exception may be Zimbabweans who are primarily in South 
Africa for employment, and who are accessing ART. Of 
course, there is also evidence that South Africans are making 
it difficult for visitors to access treatment in the public sector, 
and the appalling April 2015 xenophobic attacks sent a 
message that foreigners are not welcome in the country for 
any reason. Nevertheless, providing ART to all makes public 
health sense.
The HIV endgame: An AIDS-free 
generation
Significant scientific advances coupled with political 
will have endowed the world with effective biomedical, 
behavioural and structural interventions. The conversation 
is shifting towards a foreseeable end to the epidemic. In 
the absence of a vaccine or cure, navigating the ‘endgame’ 
will be costly and ineffective if plans are designed without 
context and foresight.
The HIV epidemic in South Africa is driven by deeply 
entrenched social and structural factors including gender 
inequality, poverty and migration.29,30 Even if the structural 
inadequacies of the healthcare system are addressed, a 
one-size-fits-all approach to HIV treatment and prevention 
will not work. The complexity of the epidemic necessitates 
a diverse range of interventions which are effective 
within the South African epidemiological and resource 
context.
Too often, health policy recommendations are prescribed 
with good intention but based primarily on modelled 
outcomes or international ‘norms’, with little attention paid 
to local context. Successful programmes that will make a 
real impact hinge on much more. Fiscal, infrastructural 
and human resources for health, political and sociocultural 
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factors drive and shape the epidemic and should inform its 
response.
Given these constraints, it is clear that a universal test and 
treat strategy, and a combination prevention and treatment 
approach that includes a strengthening of the health system, 
are mutually exclusive in the short term. A premature move 
to a one-size-fits-all policy will undermine the importance of 
other interventions that work. Rolling out a comprehensive 
treatment and prevention programme for HIV based on 
evidence for efficacy, cost-effectiveness and country-specific 
context must become a priority.
Strengthening the health system and increasing capacity 
for HIV treatment must remain high on the agenda, but 
a universal test and treat strategy cannot be pursued 
exclusively or to the detriment of other interventions that 
work, as we have shown elsewhere that there is the potential 
for a virtuous cycle to begin but it must be properly planned.31
In addition to medical interventions, there must be increased 
emphasis on gender relations and empowering women, 
especially young women. There needs to be social change, and 
it may be that requiring some form of payback for treatment – 
not financial but perhaps in terms of volunteerism – will 
contribute to this.
Conclusion
South Africa is achieving significant progress in the form of 
dramatically lower rates of mother-to-child-transmission, 
falling new infections in young adults, decreasing HIV-
related mortality, and expanding ART coverage. We cannot 
risk derailing this momentum with premature policy 
decisions. Universal access should be the primary goal and, 
in this context, treatment will necessarily lead to prevention.
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